Visual inspection: no significant deformations or damage of the valves were detected during the visual inspection.Permeability test: a permeability test has shown that both valves are permeable.Adjustment test: the progav® 2.0 valve was tested and is adjustable to all specified pressures.Braking force and brake function test: the brake functionality test has shown that the brake function is fully operational and the braking force is within the given tolerances.Computer controlled test: to investigate the claim of under-drainage, the opening pressure is measured using a miethke computer controlled testing apparatus which simulates a cerebrospinal fluid flow.Both valves are operating within acceptable tolerances.Results: first we performed a visual inspection of the progav® 2.0 shunt system.No significant deformations or damage of the valves were detected during the visual inspection.Next we tested the permeability and opening pressure of the valves.Both valves were shown to be permeable and their opening pressures were operating within specifications.Additionally, we tested the adjustability as well as the brake functionality and brake force of the progav® 2.0 valve.The valve operated as expected and met all specifications.Finally, we have dismantled the valves.There were no visible deposits observed inside the valves.Based on our investigation, we are unable to substantiate the claim of under-drainage and blockage.At the time of our investigation, the valves were operating within the specified tolerances.Despite the lack of significant deposits, it is possible that even non-visible or small amounts of build-up could have led to a temporary compromise of the valve and to the observed malfunction in the past.As described in our literature, the problem encountered is one of the known, inevitable risks of hc-therapy by shunt implants.We can exclude a defect at the time of release.The progav® 2.0 shunt system met all specifications of the final inspection when released from christoph miethke (b)(4).
|